Cargando…
The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line
Photodynamic therapy (PDT) is a low-invasive method of treatment of various diseases, mainly neoplastic conditions. PDT has been experimentally combined with multiple treatment methods. In this study, we tested a combination of 5-aminolevulinic acid (5-ALA) mediated PDT with thalidomide (TMD), which...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664331/ https://www.ncbi.nlm.nih.gov/pubmed/33171718 http://dx.doi.org/10.3390/molecules25215184 |
_version_ | 1783609822717935616 |
---|---|
author | Zduniak, Krzysztof Gdesz-Birula, Katarzyna Woźniak, Marta Duś-Szachniewicz, Kamila Ziółkowski, Piotr |
author_facet | Zduniak, Krzysztof Gdesz-Birula, Katarzyna Woźniak, Marta Duś-Szachniewicz, Kamila Ziółkowski, Piotr |
author_sort | Zduniak, Krzysztof |
collection | PubMed |
description | Photodynamic therapy (PDT) is a low-invasive method of treatment of various diseases, mainly neoplastic conditions. PDT has been experimentally combined with multiple treatment methods. In this study, we tested a combination of 5-aminolevulinic acid (5-ALA) mediated PDT with thalidomide (TMD), which is a drug presently used in the treatment of plasma cell myeloma. TMD and PDT share similar modes of action in neoplastic conditions. Using 4T1 murine breast carcinoma and 2H11 murine endothelial cells lines as an experimental tumor model, we tested 5-ALA-PDT and TMD combination in terms of cytotoxicity, apoptosis, Vascular Endothelial Growth Factor (VEGF) expression, and, in 2H11 cells, migration capabilities by wound healing assay. We have found an enhancement of cytotoxicity in 4T1 cells, whereas, in normal 2H11 cells, this effect was not statistically significant. The addition of TMD decreased the production of VEGF after PDT in 2H11 cell line. Our results reveal enhanced effectiveness of 5-ALA-PDT with TMD treatment compared to 5-ALA-PDT or TMD treatment alone. The addition of TMD may be a promising proceeding of the anti-tumor effect of PDT by decreasing the VEGF concentration in the culture medium. Further studies, including testing on different cell lines, are needed to confirm this assumption. |
format | Online Article Text |
id | pubmed-7664331 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76643312020-11-14 The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line Zduniak, Krzysztof Gdesz-Birula, Katarzyna Woźniak, Marta Duś-Szachniewicz, Kamila Ziółkowski, Piotr Molecules Article Photodynamic therapy (PDT) is a low-invasive method of treatment of various diseases, mainly neoplastic conditions. PDT has been experimentally combined with multiple treatment methods. In this study, we tested a combination of 5-aminolevulinic acid (5-ALA) mediated PDT with thalidomide (TMD), which is a drug presently used in the treatment of plasma cell myeloma. TMD and PDT share similar modes of action in neoplastic conditions. Using 4T1 murine breast carcinoma and 2H11 murine endothelial cells lines as an experimental tumor model, we tested 5-ALA-PDT and TMD combination in terms of cytotoxicity, apoptosis, Vascular Endothelial Growth Factor (VEGF) expression, and, in 2H11 cells, migration capabilities by wound healing assay. We have found an enhancement of cytotoxicity in 4T1 cells, whereas, in normal 2H11 cells, this effect was not statistically significant. The addition of TMD decreased the production of VEGF after PDT in 2H11 cell line. Our results reveal enhanced effectiveness of 5-ALA-PDT with TMD treatment compared to 5-ALA-PDT or TMD treatment alone. The addition of TMD may be a promising proceeding of the anti-tumor effect of PDT by decreasing the VEGF concentration in the culture medium. Further studies, including testing on different cell lines, are needed to confirm this assumption. MDPI 2020-11-07 /pmc/articles/PMC7664331/ /pubmed/33171718 http://dx.doi.org/10.3390/molecules25215184 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Zduniak, Krzysztof Gdesz-Birula, Katarzyna Woźniak, Marta Duś-Szachniewicz, Kamila Ziółkowski, Piotr The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line |
title | The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line |
title_full | The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line |
title_fullStr | The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line |
title_full_unstemmed | The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line |
title_short | The Assessment of the Combined Treatment of 5-ALA Mediated Photodynamic Therapy and Thalidomide on 4T1 Breast Carcinoma and 2H11 Endothelial Cell Line |
title_sort | assessment of the combined treatment of 5-ala mediated photodynamic therapy and thalidomide on 4t1 breast carcinoma and 2h11 endothelial cell line |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7664331/ https://www.ncbi.nlm.nih.gov/pubmed/33171718 http://dx.doi.org/10.3390/molecules25215184 |
work_keys_str_mv | AT zduniakkrzysztof theassessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline AT gdeszbirulakatarzyna theassessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline AT wozniakmarta theassessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline AT dusszachniewiczkamila theassessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline AT ziołkowskipiotr theassessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline AT zduniakkrzysztof assessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline AT gdeszbirulakatarzyna assessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline AT wozniakmarta assessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline AT dusszachniewiczkamila assessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline AT ziołkowskipiotr assessmentofthecombinedtreatmentof5alamediatedphotodynamictherapyandthalidomideon4t1breastcarcinomaand2h11endothelialcellline |